Neuronetics Launches Stock Offering to Fund $15M Lender Prepayment
STIM has more than doubled off its 52-week low of $0.8.
Summary
Neuronetics kicked off an underwritten public offering of new common stock, with all shares sold by the company and a 30-day option for underwriters to buy up to 15% more. No size or price was disclosed, so dilution is unknown, but the stock trades around $1.80 and the company's market value is small — any meaningful raise would be highly dilutive. The proceeds are tied to the Perceptive Sixth Amendment signed November 5, which cuts revenue covenants only if Neuronetics prepays at least $15 million plus interest, fees and costs by November 30, 2026; otherwise the amendment automatically terminates. Management says the covenant relief would resolve the going concern risk flagged in its recent 10-Q, which also disclosed an expected miss of the March 31, 2027 revenue covenant on the $65 million term loan. The setup is a forced capital raise into a weak balance sheet: existing holders absorb dilution and the stock is likely to reprice to the offering terms. Watch for the preliminary prospectus with size and pricing, and the November 30 deadline for the Perceptive prepayment conditions.
At the time of this announcement, STIM was trading at $1.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $156.2M. The 52-week trading range was $0.80 to $3.44. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.